Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Post-marketing Surveillance Study to Evaluate the Safety and Effectiveness of Atogepant for the Prevention of Migraine in Korean Adult Patients

NCT06603558 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT06603558
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06603558 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Post-marketing Surveillance Study to Evaluate the Safety and Effectiveness of Atogepant for the Prevention of Migraine in Korean Adult Patients
Lead sponsor
AbbVie
Phase
Observational
Overall status
Recruiting
Start date
September 24, 2024
Completion date
May 31, 2029
Enrollment
3,000 (estimated)
Sites
36

Conditions

As the registry lists them; a condition with its own page is linked.

chronic migraine, episodic migraine, migraine